Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
Download App
简
繁
简
繁
EN
Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
HOME
·
01672.HK
ASCLETIS-B (01672.HK): Submits FDA IND for ASC36_37o FDC in Obesity
Tags:
ASCLETIS-B
01672.HK
FDA
2026-11-17
ASCLETIS-B (01672.HK): ASC30_48 FDC Cuts Weight 52% More Than ASC30
Tags:
ASCLETIS-B
01672.HK
GLP-1
2026-11-16
Offshore Trust Insight | ASCLETIS-B (01672.HK) closes up 1.99%; Mrs. Wu holds about 7.8% of interests through discretionary trusts
Tags:
ASCLETIS-B
01672.HK
Offshore Trust
2026-11-12
ASCLETIS-B (01672.HK): files IND with US FDA for ASC30_39 FDC in obesity, a first-in-class oral combo
Tags:
ASCLETIS-B
01672.HK
FDA
2026-11-11
ASCLETIS-B (01672.HK): ASC30 Meets Phase II Diabetes Endpoint with 1.7% HbA1c Reduction
Tags:
NewTimeSpace
ASCLETIS-B
01672.HK
2026-10-29
ASCLETIS-B (01672.HK): IND for Oral Obesity Drug ASC39 Filed with US FDA
Tags:
NewTimeSpace
ASCLETIS-B
01672.HK
2026-10-26
ASCLETIS (01672.HK): Denifanstat US phase III doses first patient
Tags:
ASCLETIS
01672.HK
Clinical Progress
2026-10-23
HK Stock Connect Insight | ASCLETIS-B (01672.HK) First-Half R&D Costs Up 132.7% YoY, Down About 43% Since Stock Connect Inclusion
Tags:
ASCLETIS-B
01672.HK
HK Stock Connect
2026-10-20
ASCLETIS-B (01672.HK): Weekly oral peptide data positive
Tags:
ASCLETIS-B
01672.HK
R&D Progress
2026-10-20
ASCLETIS-B (01672.HK): ASC36_35FDC preclinical data presented at EASD 2026
Tags:
ASCLETIS-B
01672.HK
R&D Progress
2026-10-02
ASCLETIS-B (01672.HK): Initiates US Phase I Study of Oral Amylin Receptor Agonist Peptide ASC36 for Obesity; Up to 13.2% Weight Loss in Non-human Primates
Tags:
ASCLETIS-B
01672.HK
R&D Progress
2026-09-08
ASCLETIS-B (01672.HK): Included in Stock Connect list under Shanghai-Hong Kong and Shenzhen-Hong Kong schemes effective 7 September
Tags:
ASCLETIS-B
01672.HK
Stock Connect
2026-09-07
ASCLETIS-B(01672.HK)2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 319.67 million, loss widened by 263.46% YoY
Tags:
ASCLETIS-B
01672.HK
NewTimeSpace
2026-09-01
ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects
Tags:
ASCLETIS-B
01672.HK
Clinical Trial
2026-08-30
Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
Tags:
ASCLETIS-B
01672.HK
Clinical Trial
2026-08-03
ASCLETIS-B (01672.HK): ASC36_35 FDC Exhibits Superior Weight-Loss Efficacy versus Eloralintide Combined with Tirzepatide; Preclinical Data to Be Presented at EASD 2026
Tags:
ASCLETIS-B
01672.HK
preclinical data
2026-07-23
Ascletis Pharma(01672.HK): Fixed-Dose Combination of GIPR Agonist ASC48 and GLP-1R Agonist ASC30 Selected for Clinical Development
Tags:
Ascletis Pharma
01672.HK
2026-07-15
Ascletis Pharma(01672.HK): Proposed Share Repurchase of Up to HK$300 Million
Tags:
Ascletis Pharma
01672.HK
2026-06-30
Finance
METIS TECHBIO-P (07666.HK): plans H-share buyback of up to HKD 300m
Finance
HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
Research
HK Stock Connect Daily: NETEASE -17.60% on Gaming Slump - 20261120
Finance
WATER OASIS GP (01161.HK): FY profit seen doubling to HKD 165-175m
Research
HK AI Concept Stock Daily: BABA-W +3.48% Defies Slump - 20261120
Research
Hong Kong Recently Listed Stocks Daily Report: BRAINAURORA-B Rises 39.50% to Lead; Intelligent Driving and Smart Parking Gain Traction-20261120
Finance
NewTimeSpace | HK Close: HSI -1.89%, Semis and Hardware Lead Declines
Research
HK shares ETFs Daily Report: Fubon Taiwan Semiconductor ETF Falls 9.81% as CSI 300 and India Themes Rise-Nov 20, 2026
Research
Offshore Trust Insight | NIO-SW (09866.HK) -5.07%; Users Trust 50m
Research
HK Stock Connect Insight | RA MATERIALS (09607.HK) -13.26%; Stake Rise
Scan QR Code
Download App